UK Psoriasis Market Analysis

$3,000.00$7,500.00

  • Type: Common Disease Area
  • Published : February 2022
  • Region: Europe
  • Country: UK
  • Report ID : 5079

  • Format: PPT, PDF

UK Psoriasis Market Analysis: Segmented by Treatment Type, Therapeutic Type, Distribution Channel, Application- Growth, Market Size, Future Prospects & Competitive Analysis, 2020 – 2028

Clear
SKU: 5079 Categories: ,

Report Description of the UK Psoriasis Market Analysis

Research Scope and Assumption

  • The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
  • The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
  • We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
  • All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
  • Inflation has not been accounted for in order to estimate and forecast the market
  • Numbers may not add up due to rounding off

Reason to buy the report:

  • Facilitate decision-making based on strong current and forecast data for UK Psoriasis Market Analysis
  • Develop strategies based on the latest regulatory framework
  • Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
  • Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the UK Psoriasis Market Analysis
  • Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
  • To strategically profile key players and comprehensively analyze their market shares and core competencies
  • We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

UK Psoriasis Market Analysis Executive Summary

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

The health insurance system has been es-

tablished to guarantee public health in Japan

and Japan fortunately became the country

with the longest life expectancy in the world.

However, it has been forecasted that the ever-

growing medical expenses will upset the

health insurance system. In this paper, the

status quo of medical information systems is

outlined and the work on the ‘electronic

health record’ which will also be the key to

the rationalisation of the medical system in

the near future is described.

Psoriasis can be defined as a skin condition, which accelerates the life cycle of skin cells. It results in cells to develop on the surface. It is usually considered to be a chronic condition. The condition has an unpredictable course of symptoms, significant comorbidities, and various external triggers impacting the condition that includes metabolic syndrome, arthritis, and cardiovascular diseases, among others. The immune system is considered to play an integral role in the condition. The condition also affects nails apart from skin. When a particular area on the skin is affected by the disease, the skin lesion is usually localized, which are sharply demarcated by plaques and red papules that are covered by silver or white scales. These lesions are generally symmetrical and cause stinging, itching, and pain. Herein the main aim of the treatment is to prevent the skin cells from growing quickly. There is no cure to the disease; however, these drugs help in managing the symptoms.

Market Size and Key Findings

The UK Psoriasis Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Market Dynamics

Market Growth Drivers Analysis

The growth of the Psoriasis Drugs market is majorly driven by factors such as increasing public awareness, approval of new drugs Onterleukin-17 inhibitor, Taltz – ixekizumab by Eli Lily), and boost in psoriasis Research and Development investment.

Market Restraints

The key restraints of the market are the high cost involved in drug development, patent expiry of brand name drugs, side effects from the systemic and biologics medication, and health insurance issue.

COVID-19 impact on “UK Psoriasis Market Analysis” 

The COVID-19 outbreak has no significant impact on the Psoriasis treatment market. According to the companies involved in the development and manufacturing of the Psoriasis treatment products, there is no significant impact on the sales of the products especially biologics in first quarter.

Competitive Landscape

Key Players

Prominent companies dominating the UK Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).

Products in Pipeline

  • May 2019 – Mayne Pharma Group Limited announced that it has received FDA approval for the use of SORILUX Foam for the treatment of plaque psoriasis. The product is used in treatment of psoriasis of the body & scalp in patients aged 12 years and older.
  • In February 2019, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) received FDA approval to use TREMFYA, One-Press a single-dose, patient controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.

Notable Recent Deals

  • In August 2019, Amgen made an announcement to acquire Otezla, a firm involved in the production of psoriasis drugs, for a worth USD 13.40 billion.
  • In August 2019, it was announced by Amgen, Inc. that it would acquire an oral drug permitted for moderate-to-severe plaque psoriasis, Apremilast (Otezla), for USD 13.4 billion from Celgene.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

A European Expert Working Group for Healthcare in Psoriasis (EEWGHP), comprising clinicians and patient advocacy group (PAG) representatives, was convened. The EEWGHP worked between June 2010 and December 2011 to outline the specific issues in psoriasis care, and start developing clear goals and actions that would help to address them.

The goals and actions set out in this White Paper are based on the opinions of the EEWGHP, formed from extensive experience in their specialist fields and supported by relevant clinical evidence, where possible. They aim to provide a framework for improving early access to high-quality care for people with psoriasis in Europe, through raised awareness and consistent management. Ultimately, it is hoped that this framework will help to raise treatment aspirations in psoriasis (of both healthcare professionals (HCPs) and people with psoriasis), thereby improving clinical outcomes and quality of life (QoL) for people with psoriasis.

NICE said Skyrizi will be available for use in the National Health Service by adult patients whose disease is severe, as determined by a score of 10 or more in the Psoriasis Area and Severity Index and Dermatology Life Quality Index — tools used to measure the severity of psoriasis and impact of skin disease on the patient’s quality of life, respectively.

The U.K. pricing authority’s recommendation also covers patients whose disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or in cases where these treatment options are contra-indicated or not tolerated.

Patients should stop taking Skyrizi if their psoriasis has not responded adequately after 16 weeks of treatment, NICE noted.

1. Report Description of the UK Psoriasis Market Analysis
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. UK Psoriasis Market Analysis Executive Summary
2.1 UK Psoriasis Market Analysis – Industry Snapshot & key buying criteria, 2020-2028
2.2 Market Size, Growth Prospects and Key findings
3. Market Dynamics of UK Psoriasis Market Analysis
3.1 Market Growth Drivers Analysis
3.1.1 Increasing Public Awareness
3.1.2 Approval of new drugs
3.1.3 Boost in Psoriasis R&D
3.2 Market Restraints Analysis
3.2.1 High cost involved in drug development
3.2.2 Side effects from systematic medications
3.3 Covid-19 Market Impact Analysis
4. UK Psoriasis Market Segmentation
4.1 By Treatment Type:
4.1.1 Topicals
4.1.2 Systemic
4.1.3 Biologics
4.2 By Therapeutic Type:
4.2.1 Tumor Necrosis Factor Inhibitor
4.2.2 Interleukin Inhibitors
4.2.3 Anti-Inflammatory
4.2.4 Corticosteroids
4.3 By Distribution Channel:
4.3.1 Hospitals and Clinics
4.3.2 E-commerce
4.3.3 Retail Pharmacies
4.4 By Application:
4.4.1 Plaque Psoriasis
4.4.2 Guttate Psoriasis
4.4.3 Nail Psoriasis
4.4.4 Erythrodermic Psoriasis
4.4.5 Pustular Psoriasis
4.4.6 Intertriginous psoriasis
4.4.7 Others
5. UK Psoriasis Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
6.2 Products in Pipeline
6.3 R&D Initiatives in Psoriasis Market
6.4 Notable recent deals in Psoriasis Market
6.4.1 Joint Ventures
6.4.2 Partnerships
6.4.3 Mergers & Acquisitions
6.4.4 Strategic divestments
7. Key Company Profiles
7.1 Johnson & Johnson Company overview
Product & Services, Strategies & Financials
7.2 Novartis International Company overview
Product & Services, Strategies & Financials
7.3 Pfizer Inc. Company overview
Product & Services, Strategies & Financials
7.4 Merck and Co. Inc. Company overview
Product & Services, Strategies & Financials
7.5 Celgene Corporation Company overview
Product & Services, Strategies & Financials
7.6 Janssen Biotech Company overview
Product & Services, Strategies & Financials
7.7 Amgen Company overview
Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
9. Factors Driving Future Growth
9.1 New Trends and Development of Psoriasis market
9.2 Future Opportunities
10. Strategic Recommendations

UK Psoriasis Market Analysis Segmentation

By Treatment Type:

By Treatment Type, the Biologics segment contributed to the largest market share in 2019. Biologics are usually given by injection, and these are usually recommended to care for users who do not respond to traditional therapy or have associated psoriatic arthritis. The market share occupied by the segment is attributed to its ability to treat the condition by targeting particular areas of the immune system, thereby treating the condition form the base, which results in its high acceptance among care providers.

By Therapeutic Type:

By Therapeutic Class, it can be observed that the Tumor Necrosis Factor Inhibitor segment held the largest market share in 2019. The applicability of this therapeutic class in reducing inflammation, which is a common symptom associated with the condition and one of the primary goals of the care service is to reduce it, contributes to the market share occupied by this segment.

By Distribution Channel:

By Distribution Channel, it can be observed that the Hospitals and Clinics segment is leading the market occupying the largest market share. The high dependency on this distribution channel for availing drugs associated with the condition like Systemic medications and Phototherapy contributes to the market share occupied by this segment.

By Application:

By Application, the Nail Psoriasis segment is projected to witness a considerable growth rate. The growth rate experienced by the Nail Psoriasis segment is resultant of a high occurrence rate of the condition, increasing awareness about it, which in turn propels the demand for these drugs to treat Nail Psoriasis.

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.



    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements